Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now


Peer Review Publication of Agluna® Clinical Outcome Data

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to report the publication in a leading peer review orthopaedic journal of the case-control study demonstrating significant infection rate reduction in high-risk patients receiving Agluna® treated custom limb salvage devices. The Agluna® technology is currently supplied by Accentus Medical under licence to Stanmore Implants on its custom (patient specific) limb salvage devices.

Published in February edition of The Bone & Joint Journal, the clinical paper reports a case-control study undertaken at the Royal Orthopaedic Hospital, Birmingham, in which 85 patients receiving Agluna® treated tumour implants between 2006 and 2011 were matched with 85 control patients receiving identical un-treated implants between 2001 and 2011.

The key reported clinical outcomes are as follows:

• Overall reduction in post-operative infection rates from 22.4% in the control group to 11.8% in the Agluna® group;
• Success rates with DAIR (debridement, antibiotics and implant retention) increased from 31.6% (control group) to 70% (Agluna® group);
• Persistent periprosthetic infection necessitating device removal, amputation or chronic antibiotics suppression reduce from 15.3% (control group)to 3.5% (Agluna® group);
• Success rates with two-stage revisions increased from 57.1% (control group) to 85% (Agluna® group).

Philip Agg, Chief Executive, said “We are delighted that evidence of the very positive clinical outcomes being experienced by clinical end users of the Agluna® technology has now been published in The Bone & Joint Journal. Devices with Agluna® surface modification are demonstrating the clinical benefits of optimising surface concentration and release profile of silver ions. We are now looking to bring the benefits of Agluna® to a wider range of clinical end users in the growing orthopaedic device sector.”


For further information, please contact:
Philip Agg, CEO
T: +44 (0)1235 434328